Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

Metformin Repurposing for FMR1-Associated Metabolic Dysfunction

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19833993

Metformin Repurposing for FMR1-Associated Metabolic Dysfunction

Abstract

Clinical trial NCT03862950 completed testing metformin in FXS patients. FAERS data shows hydroxychloroquine (6 reports) and sulfasalazine (7 reports) co-reported with FXS, both drugs affecting similar metabolic/inflammatory pathways as metformin. Metformin may restore mTOR signaling and protein synthesis balance disrupted in FXS.

Powered by OpenAIRE graph
Found an issue? Give us feedback